Renal cell carcinoma-associated cell surface antigens (RCC-associated cell surface antigens)

RCC-associated cell surface antigens represent a diverse collection of proteins expressed on the surface of renal cell carcinoma cells, particularly clear cell renal cell carcinoma (ccRCC). These antigens can be classified as tumor-associated antigens (TAAs) that are derived from overexpressed genes, differentiation markers, or cancer germline antigens. Key examples include carbonic anhydrase 9 (CA9), which maintains neutral pH in the acidic tumor microenvironment and is highly expressed in ccRCC; CD70, a co-stimulatory molecule normally found on dendritic cells but commonly overexpressed in ccRCC; and MUC1, a transmembrane glycoprotein related to kidney development. These surface antigens serve as potential targets for various immunotherapeutic approaches including monoclonal antibodies, CAR-T cell therapies, and cancer vaccines. Unlike many other cancers responsive to immune checkpoint inhibitors, RCC has a modest mutation burden, making these tumor-associated surface antigens particularly important therapeutic targets. The identification and targeting of these antigens is critical for developing more effective and safer immunotherapies for RCC, though challenges remain in balancing efficacy with on-target, off-tumor toxicity when these antigens are also expressed in normal tissues.

Other names

RCC surface antigensRenal cell carcinoma cell surface markersccRCC surface antigens (when specifically referring to clear cell RCC)

Antibody-dependent cellular cytotoxicity CAR-T cell-mediated tumor cell killing Immune checkpoint modulation Direct targeting of tumor cell surface proteins